Completed PHASE4 INTERVENTIONAL NCT00295685

Nexium 40mg Once Daily vs Prevacid 30mg Twice a Day for Control of Severe GERD

Single Dose Nexium 40MG QAM vs Lansoprazole 30mg BID for Control of Symptomatic GERD-A Double Blind Cross-Over Study

Sponsor: AstraZeneca

Conditions GERD

Interventions Antacids

Updated 5 times since 2017 Last updated: Feb 24, 2009 Started: Oct 31, 2005 Completion: Dec 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00295685, this PHASE4 trial focuses on GERD and remains completed. Sponsored by AstraZeneca, it has been updated 5 times since 2005, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Oct 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca
Digestive & Liver Disease Specialists

Data source: Digestive & Liver Disease Specialists

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Norfolk, United States